UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of report (date of earliest event reported): March 5, 2018
OWC Pharmaceutical Research Corp.
(Exact Name of Registrant as Specified in its Charter)
Commission File No.: 0-54856
Delaware | | 98-0573566 |
(State of Incorporation) | | (I.R.S. Employer Identification No.) |
| | |
2 Ben Gurion Street, Ramat Gan, Israel | | 4514760 |
(Address of Principal Executive Offices) | | (Zip Code) |
Registrant’s Telephone Number, including area code: 972 (0) 3-758-2657
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
[ ] | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
[ ] | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
[ ] | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
[ ] | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 8.01. Other Events.
OWC Pharmaceutical Research Corp. (the “Registrant”), is filing with this Form 8-K, a link to a video interview of Dr. Stanley Hirsch, Chairman of the Registrant’s Board of Directors, conducted by Mike Elliott of CEOlive at the 2018 Wall Street Conference held in Deerfield Beach, FL on February 21, 2018. The link to the video conference referenced in Exhibit 99.1 hereto, is:https://www.youtube.com/watch?v=VkW7_56ZSv0&feature=youtu.be
For information regarding the Registrant and to view its news and video releases including the interview of Dr. Hirsch, please visit the Registrant’s website at:
http://www.owcpharma.com/newsroom-photos/
Item 9.01 Financial Statements and Exhibits.
(a) The following documents are filed as exhibits to this report on Form 8-K or incorporated by reference herein. Any document incorporated by reference is identified by a parenthetical reference to the SEC filing that included such document.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
OWC Pharmaceutical Research Corp. | |
| | |
By: | /s/ Mordechai Bignitz | |
Name: | Mordechai Bignitz | |
Title: | Chief Executive Officer | |
Date: March 5, 2018